Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2011 Sep;254(3):527-37; discussion 537-8.
doi: 10.1097/SLA.0b013e31822ca66f.

Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma?

Affiliations
Comparative Study

Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma?

Leonidas G Koniaris et al. Ann Surg. 2011 Sep.

Abstract

Objective: To compare outcomes for patients with hepatocellular carcinoma (HCC) treated with either liver resection or transplantation.

Methods: A retrospective, single-institution analysis of 413 HCC patients from 1999 to 2009.

Results: A total of 413 patients with HCC underwent surgical resection (n = 106) and transplantation (n = 270) or were listed without receiving transplantation (n = 37). Excluding transplanted patients with incidental tumors (n = 50), 257 patients with suspected HCC were listed with the intent to transplant (ITT). The median diameter of the largest tumor by radiography was 6.0 cm in resected, 3.0 cm in transplanted, and 3.4 cm in the listed-but-not-transplanted patients. Median time to transplant was 48 days. Recurrence rates were 19.8% for resection and 12.1% for all ITT patients. Overall, patient survival for resection versus ITT patients was similar (5-year survival of 53.0% vs 52.0%, not significant). However, for HCC patients with model end-stage liver disease (MELD) scores less than 10 and who radiologically met Milan or UCSF (University of California, San Francisco) criteria, 1-year and 5-year survival rates were significantly improved in resected patients. For patients with MELD score less than 10 and who met Milan criteria, 1-year and 5-year survival were 92.0% and 63.0% for resection (n = 26) versus 83.0% and 41.0% for ITT (n = 73, P = 0.036). For those with MELD score less than 10 and met UCSF criteria, 1-year and 5-year survival was 94.0% and 62.0% for resection (n = 33) versus 81.0% and 40.0% for ITT (n = 78, P = 0.027).

Conclusions: Among known HCC patients with preserved liver function, resection was associated with superior patient survival versus transplantation. These results suggest that surgical resection should remain the first line therapy for patients with HCC and compensated liver function who are candidates for resection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient stratification by Milan, UCSF criteria and MELD score.
Figure 2
Figure 2
Radiographic tumor size versus MELD score for resection and intent to transplant patients.
Figure 3
Figure 3
Overall Percent Survival for patients satisfying current UNOS criteria (Milan Criteria) comparing hepatic resection versus non-incidental transplant and listed but not transplanted patients.
Figure 4
Figure 4
Resection versus intent to transplant overall survival using the Kaplan-Meier method. (P-Values via Log Rank (Mantel Cox) Method. A) Restricted to patients meeting the Milan criteria. B) Patients meeting the Milan criteria with MELD score below 10. C) Restricted to patients meeting the UCSF criteria. D) Patients meeting the UCSF criteria with MELD score below 10.
Figure 5
Figure 5
Recurrence free survival for all hepatic resection and transplant patients excluding incidentally identified hepatocellular carcinomas.
Figure 6
Figure 6
Recurrence free survival for hepatic resection and transplant patients excluding incidentally identified hepatocellular carcinomas by tumor size for all MELD or MELD under 10. A) Milan Criteria, B) UCSF Criteria, C) Milan Criteria with MELD <10 and D) UCSF Criteria with MELD <10.

References

    1. World Health Organization. [Accessed May 1, 2011]; Website: http://www.who.int/mediacentre/factsheets/fs297/en/index.html.
    1. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127(5) Suppl 1:S27–S34. - PubMed
    1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5) Suppl 1:S5–S16. - PubMed
    1. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 1997;25(3):754–758. - PubMed
    1. McKillop IH, Moran DM, Jin X, Koniaris LG. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res. 2006;136(1):125–135. - PubMed

Publication types

MeSH terms